Abstract: The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
July 11, 2023
Assignee:
The Regents of the University of Michigan
Inventors:
Arul M. Chinnaiyan, Dan Robinson, Yi-Mi Wu
Abstract: A method of providing information for predicting a risk of a recurrence after treatment of a patient with paroxysmal atrial fibrillation (AF) is provided. The method includes measuring a concentration of tissue inhibitor of metalloproteinase (TIMP)-1 from a sample isolated from a patient, and detecting a presence of a genetic variant at rs10033464 GG on chromosome 4q25 from nucleic acid separated from the sample.
Type:
Grant
Filed:
July 14, 2020
Date of Patent:
June 27, 2023
Assignee:
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstitial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.
Type:
Grant
Filed:
February 1, 2021
Date of Patent:
June 13, 2023
Assignees:
Icahn School of Medicine at Mount Sinai, Western Sydney Local Health District
Inventors:
Barbara Murphy, Weijia Zhang, Philip J. O'Connell
Abstract: A method to predict an increased risk of a greater susceptibility to a metal implant sensitivity in a test person. The method includes providing an isolated sample with a genetic material of the test person, and examining a single nucleotide polymorphism rs1143627 SEQ?ID?NO:?1 AGCCTCCTACTTCTGCTTTTGAAAGC[C/T]ATAAAA ACAGCGAGGGAGAACTGG,? in a gene coding for interleukin 1 beta and ascertaining whether a C is present at a position of the single nucleotide polymorphism, and/or examining a VNTR polymorphism rs2234663 with the repeat SEQ?ID?NO:?2 ATCCTGGGGAAAGTGAGGGAAATATGGACATCACATGGAACAACAT CCAGGAGACTCAGGCCTCTAGGAGTAACTGGGTAGTGTGC, in a gene coding for a IL1 receptor antagonist, IL1-RN and ascertaining whether the repeat is present five times.
Type:
Grant
Filed:
February 4, 2019
Date of Patent:
May 16, 2023
Assignee:
KLINIKUM DER UNIVERSITAET MUENCHEN
Inventors:
Burkhard Summer, Peter Thomas, Sylvia Usbeck, Diana Lill
Abstract: Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
April 18, 2023
Assignee:
Tempus Labs, Inc.
Inventors:
Ameen Salahudeen, Verónica Sánchez Freire, Brandon L. Mapes
Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
Abstract: The present disclosure provides methods, systems, compositions, and kits for the high-throughput detection of multi-molecule biomarkers in a biological sample. The disclosed methods, systems, compositions, and kits utilize antibody-oligonucleotide tags to detect two or more molecules that are in close proximity.
Abstract: The invention provides a gene signature for use in determining a likelihood of a latent tuberculosis (TB) infection in a subject transitioning to active TB disease. The gene signature comprises at least SEPT4 and BLK, and optionally also GAS6 and/or CD1C. Expression levels of these genes are detected in a sample from the subject, and the ratios of expression of at least two of the above genes are calculated (e.g. SEPT4:BLK, SEPT4:CD1C, GAS6:BLK and/or GAS6:CD1C). A score is assigned to each ratio, the score being indicative of the likelihood of the latent TB infection transitioning into active TB disease, based on the ratio for the respective gene pair. The subject can be identified as having a latent TB infection that is likely to transition into active TB disease or that is not likely to transition into active TB disease based on the score or on the average of the scores.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
March 28, 2023
Assignees:
UNIVERSITY OF CAPE TOWN, STELLENBOSCH UNIVERSITY, SEATTLE CHILDREN'S HOSPITAL, MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V, UNITED KINGDOM RESEARCH AND INNOVATION
Inventors:
Sara Suliman, Ethan Greene Thompson, Jayne Suzanne Sutherland, Stefan H. E. Kaufmann, Thomas Jens Scriba, Daniel Edward Zak, Gerhard Walzl
Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
February 14, 2023
Assignee:
Becton, Dickinson and Company
Inventors:
James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample f a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
February 27, 2020
Date of Patent:
January 3, 2023
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: The present invention is directed to methods and kits for determining the presence of a mutated SLC30A2 polynucleotide. The invention is further directed to methods of determining a subject's genetic-susceptibility to zinc deficiency and evaluating zinc levels in a composition comprising breast milk.
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
December 20, 2022
Assignee:
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
December 6, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
December 6, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
November 29, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
March 18, 2020
Date of Patent:
November 15, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
November 1, 2022
Assignees:
Toray Industries, Inc., National Cancer Center
Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
February 21, 2020
Date of Patent:
October 25, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
October 25, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER